The combination of strong financial performance, margin expansion from yield-enhanced production, and leadership continuity with an experienced CFO suggests sustained growth momentum. Traders should monitor execution against the aggressive 2026 guidance of >$635 million revenue.
Price Chart
Executive Summary
ADMA Biologics reported record financial results for 2025 with 20% YoY revenue growth to $510 million and 35% growth in Adjusted Net Income to $161 million, driven by strong ASCENIV demand. The company also announced the retirement of CFO Brad Tade and the appointment of Terry Kohler as his successor, effective February 26, 2026, with Tade transitioning to a consulting role through July 2026.
Key Financial Metrics
Key Facts
- FY 2025 total revenue of $510.2 million, up 20% YoY
- ASCENIV revenue grew 51% YoY to $363 million
- FY 2025 Adjusted Net Income of $160.8 million, up 35% YoY
- FY 2025 Adjusted EBITDA of $231 million, up 40% YoY
- CFO Brad Tade retiring, succeeded by Terry Kohler effective February 26, 2026
- Company reiterated 2026-2029 guidance with FY 2026 revenue expected to exceed $635 million
Financial Impact
Revenue growth of $83.7 million YoY with expanding margins; gross margin improved to 57.4% from 51.5% in 2024
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| ASCENIV | $362.5M | +51.0% |
| BIVIGAM | $122.0M | -14.0% |
Risk Factors
- Potential execution risk in leadership transition despite structured handover
- Dependence on continued ASCENIV market penetration and payer coverage
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-006781 |
| Document: ef20066393_ex10-2.htm | 0001140361-26-006781 |
| Document: ef20066393_ex10-1.htm | 0001140361-26-006781 |
| Document: ef20066393_8k.htm | 0001140361-26-006781 |
| Document: 0001140361-26-006781-index-headers.html | 0001140361-26-006781 |
| Document: 0001140361-26-006781-index.html | 0001140361-26-006781 |
| Document: 0001140361-26-006781.txt | 0001140361-26-006781 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | Press Release | $10.73 | awaiting T+60 | — | $10.98 (+2.28%) |
Aug 8, 2026 11w ago | Institutional Cluster | $9.75 | awaiting T+60 | — | $10.98 (+12.56%) |
Jun 11, 2026 19w ago | Institutional Cluster | $8.21 $9.54 | ▲ +16.20% | ▲ +12.94% | $10.98 (+33.68%) |
May 4, 2026 25w ago | 8-K | $10.31 $8.71 | ▼ −15.52% | ▼ −17.38% | $10.98 (+6.45%) |
Apr 15, 2026 27w ago | DEFA14A | $10.74 $8.97 | ▼ −16.48% | ▼ −23.53% | $10.98 (+2.19%) |
Mar 27, 2026 30w ago | Press Release | $9.25 $8.72 | ▼ −5.78% | ▼ −21.85% | $10.98 (+18.65%) |
Feb 25, 2026 34w ago | 8-K | $15.18 $8.46 | ▼ −44.27% | ▼ −52.02% | $10.98 (−27.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers